<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="9425bf9f-6935-407b-b972-dfdc302fadc3"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.<br/>MOUNJARO<sup>Â®</sup> (tirzepatide) Injection, for subcutaneous use <br/>Initial U.S. Approval: 2022
</title>
   <effectiveTime value="20250408"/>
   <setId root="d2d7da5d-ad07-4228-955f-cf7e355c8cc0"/>
   <versionNumber value="23"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="006421325" root="1.3.6.1.4.1.519.1"/>
            <name>Eli Lilly and Company</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="70b7ecd8-6a05-492b-8522-1c11997b2867"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20230728"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1506" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-1506-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1506-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220513"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1506-61" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220608"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220513"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1495" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-1495-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1495-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220513"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220513"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1484" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-1484-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1484-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220513"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220513"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1471" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-1471-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1471-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220513"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220513"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1460" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-1460-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1460-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220513"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220513"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1457" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-1457-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1457-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220513"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220513"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1152" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1152-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230728"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230728"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1243" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1243-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230728"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230728"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2214" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2214-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230728"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230728"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2340" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2340-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230728"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230728"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2423" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2423-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230728"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230728"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-3002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOUNJARO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-3002-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230728"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230728"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215866" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s0">
               <id root="d44733f2-de4f-4754-9a40-bfffcdc427e7"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90.000%" align="left"/>
                           <col width="10.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top">Warnings and Precautions
</td>
                                 <td/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Â  Â   Severe Gastrointestinal Adverse Reactions (<linkHtml href="#s15">5.6</linkHtml>)
</td>
                                 <td align="right" valign="top">11/2024
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Â  Â   Pulmonary Aspiration During General Anesthesia or Deep Sedation (<linkHtml href="#s17a">5.9</linkHtml>)
</td>
                                 <td align="right" valign="top">11/2024
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="08e0aab5-e6f9-4a91-949c-8151b75d3f37"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK OF THYROID C-CELL TUMORS
</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined
</content>
                        <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>) and Nonclinical Toxicology (<linkHtml href="#s72">13.1</linkHtml>)].</content>
                     </item>
                     <item>
                        <content styleCode="bold">MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome typeÂ 2 (MENÂ 2)
</content>
                        <content styleCode="bold italics">[see Contraindications (<linkHtml href="#s8">4</linkHtml>)]</content>
                        <content styleCode="bold">. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO
</content>
                        <content styleCode="bold italics">[see Contraindications (<linkHtml href="#s8">4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20220513"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: RISK OF THYROID C-CELL TUMORS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined (<linkHtml href="#s10">5.1</linkHtml>, <linkHtml href="#s72">13.1</linkHtml>).</content>
                           </item>
                           <item>
                              <content styleCode="bold">MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome typeÂ 2 (MENÂ 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (<linkHtml href="#s8">4</linkHtml>, <linkHtml href="#s10">5.1</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="0b3e1306-9e78-408e-8d26-f559d1fc5591"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>MOUNJARO<sup>Â®</sup> is indicated as an adjunct to diet and exercise to improve glycemic control in adults with typeÂ 2 diabetes mellitus.
</paragraph>
               </text>
               <effectiveTime value="20230515"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>MOUNJARO<sup>Â®</sup> is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with typeÂ 2 diabetes mellitus. (<linkHtml href="#s2">1</linkHtml>)
</paragraph>
                        <paragraph>Limitations of Use:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Has not been studied in patients with a history of pancreatitis (<linkHtml href="#s2">1</linkHtml>, <linkHtml href="#s11">5.2</linkHtml>)
</item>
                           <item>Is not indicated for use in patients with typeÂ 1 diabetes mellitus (<linkHtml href="#s2">1</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="7049777c-ec8f-459f-b330-e4c4849bac10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>MOUNJARO has not been studied in patients with a history of pancreatitis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>.
</item>
                           <item>MOUNJARO is not indicated for use in patients with typeÂ 1 diabetes mellitus.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s4">
               <id root="3bf2e823-c283-470c-af42-67d541093136"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended starting dosage is 2.5Â mg injected subcutaneously once weekly (<linkHtml href="#s5">2.1</linkHtml>)
</item>
                           <item>After 4 weeks, increase to 5Â mg injected subcutaneously once weekly (<linkHtml href="#s5">2.1</linkHtml>)
</item>
                           <item>If additional glycemic control is needed, increase the dosage in 2.5Â mg increments after at least 4 weeks on the current dose.
</item>
                           <item>The maximum dosage is 15Â mg subcutaneously once weekly (<linkHtml href="#s5">2.1</linkHtml>).
</item>
                           <item>Administer once weekly at any time of day, with or without meals. (<linkHtml href="#s6">2.2</linkHtml>)
</item>
                           <item>Inject subcutaneously in the abdomen, thigh, or upper arm. (<linkHtml href="#s6">2.2</linkHtml>)
</item>
                           <item>Rotate injection sites with each dose.
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s5">
                     <id root="2bea1350-5e9f-4878-bb48-f9c68e94cba6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Dosage
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended starting dosage of MOUNJARO is 2.5Â mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.6</linkHtml>) and Adverse Reactions (<linkHtml href="#s19">6.1</linkHtml>)]</content>. The 2.5Â mg dosage is for treatment initiation and is not intended for glycemic control.
</item>
                           <item>After 4 weeks, increase the dosage to 5Â mg injected subcutaneously once weekly.
</item>
                           <item>If additional glycemic control is needed, increase the dosage in 2.5Â mg increments after at least 4 weeks on the current dose.
</item>
                           <item>The maximum dosage of MOUNJARO is 15Â mg injected subcutaneously once weekly.
</item>
                           <item>If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
</item>
                           <item>The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).
</item>
                        </list>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="a8770320-2626-4a7c-a529-6b6a5bf71a0e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Important Administration Instructions
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Prior to initiation, train patients and caregivers on proper injection technique <content styleCode="italics">[see <linkHtml href="#s97">Instructions for Use</linkHtml>]</content>.
</item>
                           <item>Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1Â mL syringe capable of measuring a 0.5Â mL dose).
</item>
                           <item>Administer MOUNJARO once weekly, any time of day, with or without meals.
</item>
                           <item>Inject MOUNJARO subcutaneously in the abdomen, thigh, or upper arm.
</item>
                           <item>Rotate injection sites with each dose.
</item>
                           <item>Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen.
</item>
                           <item>When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="70ac44f1-d253-4557-8885-f3eb3c05fff1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens or single-dose vials, each available in the following strengths:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>2.5Â mg/0.5Â mL
</item>
                     <item>5Â mg/0.5Â mL
</item>
                     <item>7.5Â mg/0.5Â mL
</item>
                     <item>10Â mg/0.5Â mL
</item>
                     <item>12.5Â mg/0.5Â mL
</item>
                     <item>15Â mg/0.5Â mL
</item>
                  </list>
               </text>
               <effectiveTime value="20220513"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 2.5Â mg, 5Â mg, 7.5Â mg, 10Â mg, 12.5Â mg, or 15Â mg per 0.5Â mL in single-dose pen or single-dose vial (<linkHtml href="#s7">3</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="614149f1-fa01-490c-8956-00391793e81a"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>MOUNJARO is contraindicated in patients with:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome typeÂ 2 (MENÂ 2) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>.
</item>
                     <item>Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>.
</item>
                  </list>
               </text>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (<linkHtml href="#s8">4</linkHtml>, <linkHtml href="#s10">5.1</linkHtml>)
</item>
                           <item>Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO (<linkHtml href="#s8">4</linkHtml>, <linkHtml href="#s13">5.4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="8d38a916-e5f8-44cc-b5fb-c2b4305272c0"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics"/>
                              <content styleCode="italics">Pancreatitis:</content> Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. (<linkHtml href="#s11">5.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics"/>
                              <content styleCode="italics">Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin:</content> Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. (<linkHtml href="#s12">5.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypersensitivity Reactions:</content> Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue MOUNJARO if suspected and promptly seek medical advice. (<linkHtml href="#s13">5.4</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics"/>
                              <content styleCode="italics">Acute Kidney Injury:</content> Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. (<linkHtml href="#s14">5.5</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics"/>
                              <content styleCode="italics">Severe Gastrointestinal Adverse Reactions:</content> Use may be associated with gastrointestinal adverse reactions, sometimes severe. Has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients. (<linkHtml href="#s15">5.6</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics"/>
                              <content styleCode="italics">Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy:</content> Has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Monitor patients with a history of diabetic retinopathy for progression. (<linkHtml href="#s16">5.7</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Acute Gallbladder Disease:</content> Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated. (<linkHtml href="#s17">5.8</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Pulmonary Aspiration During General Anesthesia or Deep Sedation:</content> Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures. (<linkHtml href="#s17a">5.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s10">
                     <id root="2925fcde-306a-4237-b6b6-bf17e0c52318"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk of Thyroid C-Cell Tumors
</title>
                     <text>
                        <paragraph>In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#s72">13.1</linkHtml>)]</content>. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
</paragraph>
                        <paragraph>MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MENÂ 2. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
</paragraph>
                        <paragraph>Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values &gt;50Â ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="4a856e45-a73f-46d0-852b-052e56353494"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Pancreatitis
</title>
                     <text>
                        <paragraph>Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.
</paragraph>
                        <paragraph>In clinical studies, 14 events of acute pancreatitis were confirmed by adjudication in 13 MOUNJARO-treated patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). MOUNJARO has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on MOUNJARO.
</paragraph>
                        <paragraph>After initiation of MOUNJARO, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue MOUNJARO and initiate appropriate management.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="5246b079-adc5-4e54-9f4c-4b97b98c7073"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
</title>
                     <text>
                        <paragraph>Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s19">6.1</linkHtml>), Drug Interactions (<linkHtml href="#s33">7.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="48664af6-fed9-4e07-afc9-0764504aad17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hypersensitivity Reactions
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with MOUNJARO. If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in MOUNJARO <content styleCode="italics">[see Contraindications (<linkHtml href="#s8">4</linkHtml>), Adverse Reactions (<linkHtml href="#s31">6.2</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with MOUNJARO.
</paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="99f216cd-072a-4dd6-a5f3-4cd6e643247f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Acute Kidney Injury
</title>
                     <text>
                        <paragraph>MOUNJARO has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s19">6.1</linkHtml>)]</content>. These events may lead to dehydration, which if severe could cause acute kidney injury.
</paragraph>
                        <paragraph>In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe gastrointestinal adverse reactions.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="b4cdeb35-4910-4048-815f-cbd604976f63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Severe Gastrointestinal Adverse Reactions
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Use of MOUNJARO has been associated with gastrointestinal adverse reactions, sometimes severe <content styleCode="italics">[see Adverse Reactions <linkHtml href="#s19">6.1</linkHtml>]</content>. In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%). </paragraph>
                        <paragraph>MOUNJARO has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="c44981b7-24b2-4c94-b760-0e20b596a149"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy
</title>
                     <text>
                        <paragraph>Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. MOUNJARO has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="14c6fe17-c59e-4ef6-9d28-c67e3946d522"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Acute Gallbladder Disease
</title>
                     <text>
                        <paragraph>Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.
</paragraph>
                        <paragraph>In MOUNJARO placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s17a">
                     <id root="e0797365-03ca-4e9c-bbcc-601e7a19fdc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>MOUNJARO delays gastric emptying <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s54">12.2</linkHtml>)]</content>. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking MOUNJARO, including whether modifying preoperative fasting recommendations or temporarily discontinuing MOUNJARO could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking MOUNJARO.
</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s18">
               <id root="dbe15a83-3ec5-496d-8af2-5d89e77d945d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following serious adverse reactions are described below or elsewhere in the prescribing information:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Risk of Thyroid C-cell Tumors <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>
                     </item>
                     <item>Pancreatitis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>
                     </item>
                     <item>Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>
                     </item>
                     <item>Acute Kidney Injury <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.5</linkHtml>)]</content>
                     </item>
                     <item>Severe Gastrointestinal Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.6</linkHtml>)]</content>
                     </item>
                     <item>Diabetic Retinopathy Complications <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.7</linkHtml>)]</content>
                     </item>
                     <item>Acute Gallbladder Disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.8</linkHtml>)]</content>
                     </item>
                     <item>Pulmonary Aspiration During General Anesthesia or Deep Sedation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17a">5.9</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions, reported in â¥5% of patients treated with MOUNJARO are: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. (<linkHtml href="#s19">6.1</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s19">
                     <id root="1749004e-a3eb-46fc-bd22-609bbc231bd6"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                     <component>
                        <section ID="s20">
                           <id root="e30d3d46-5c20-43d7-b994-f7ae47ab961a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pool of Two Placebo-Controlled Clinical Trials</content>
                              </paragraph>
                              <paragraph>The data in <linkHtml href="#t1">TableÂ 1</linkHtml> are derived from 2 placebo-controlled trials [1 monotherapy trial (SURPASS-1) and 1 trial in combination with basal insulin with or without metformin (SURPASS-5)] in adult patients with typeÂ 2 diabetes mellitus <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s75">14.2</linkHtml>, <linkHtml href="#s80">14.4</linkHtml>)]</content>. These data reflect exposure of 718 patients to MOUNJARO and a mean duration of exposure to MOUNJARO of 36.6 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 54% were male. The population was 57% White, 27% Asian, 13% American Indian or Alaska Native, and 3% Black or African American; 25% identified as Hispanic or Latino ethnicity. At baseline, patients had typeÂ 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.1%. As assessed by baseline fundoscopic examination, 13% of the population had retinopathy. At baseline, eGFR was â¥90Â mL/min/1.73Â m<sup>2</sup> in 53%, 60 to 90Â mL/min/1.73Â m<sup>2</sup> in 39%, 45 to 60Â mL/min/1.73Â m<sup>2</sup> in 7%, and 30 to 45Â mL/min/1.73Â m<sup>2</sup> in 1% of patients.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s21">
                           <id root="eeb9b9a6-593c-4a5a-a329-35624e482d54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pool of Seven Controlled Clinical Trials</content>
                              </paragraph>
                              <paragraph>Adverse reactions were also evaluated in a larger pool of adult patients with type 2 diabetes mellitus participating in seven controlled clinical trials which included two placebo-controlled trials (SURPASS-1 and -5), three trials of MOUNJARO in combination with metformin, sulfonylureas, and/or SGLT2 Inhibitors (SURPASS-2, -3, -4) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s76">14.3</linkHtml>)]</content> and two additional trials conducted in Japan. In this pool, a total of 5119 adult patients with typeÂ 2 diabetes mellitus were treated with MOUNJARO for a mean duration of 48.1 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 58% were male. The population was 65% White, 24% Asian, 7% American Indian or Alaska Native, and 3% Black or African American; 38% identified as Hispanic or Latino ethnicity. At baseline, patients had typeÂ 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.3%. As assessed by baseline fundoscopic examination, 15% of the population had retinopathy. At baseline, eGFR was â¥90Â mL/min/1.73Â m<sup>2</sup> in 52%, 60 to 90Â mL/min/1.73Â m<sup>2</sup> in 40%, 45 to 60Â mL/min/1.73Â m<sup>2</sup> in 6%, and 30 to 45Â mL/min/1.73Â m<sup>2</sup> in 1% of patients.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s22">
                           <id root="9134423e-ba45-42ba-b8db-eae17c3ec225"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Common Adverse Reactions</content>
                              </paragraph>
                              <paragraph>
                                 <linkHtml href="#t1">Table 1</linkHtml> shows common adverse reactions, not including hypoglycemia, associated with the use of MOUNJARO in the pool of placebo-controlled trials. These adverse reactions occurred more commonly on MOUNJARO than on placebo and occurred in at least 5% of patients treated with MOUNJARO.
</paragraph>
                              <table ID="t1" width="100%">
                                 <caption>TableÂ 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in â¥5% of MOUNJARO-treated Adult Patients with TypeÂ 2 Diabetes Mellitus
</caption>
                                 <col width="24.040%" align="left"/>
                                 <col width="19.240%" align="left"/>
                                 <col width="18.260%" align="left"/>
                                 <col width="20.200%" align="left"/>
                                 <col width="18.260%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">Note: Percentages reflect the number of patients who reported at least 1 occurrence of the adverse reaction.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reaction</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Placebo<br/>(N=235)<br/>%</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO <br/>5Â mg<br/>(N=237)<br/>%</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO <br/>10Â mg<br/>(N=240)<br/>%</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO <br/>15Â mg<br/>(N=241)<br/>%</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Nausea
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">15
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">18
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">17
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased Appetite
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Vomiting
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Constipation
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Dyspepsia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Abdominal Pain
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the pool of seven clinical trials, the types and frequency of common adverse reactions, not including hypoglycemia, were similar to those listed in <linkHtml href="#t1">TableÂ 1</linkHtml>.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s23">
                           <id root="d6ca3b6d-9a57-4b1e-b9ed-c16ce747537a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal Adverse Reactions</content>
                              </paragraph>
                              <paragraph>In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5Â mg 37.1%, MOUNJARO 10Â mg 39.6%, MOUNJARO 15Â mg 43.6%). More patients receiving MOUNJARO 5Â mg (3.0%), MOUNJARO 10Â mg (5.4%), and MOUNJARO 15Â mg (6.6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.
</paragraph>
                              <paragraph>The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5Â mg; 10Â mg; 15Â mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s24">
                           <id root="fad8032e-b960-4f98-8fb3-1047b6347a5c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Adverse Reactions</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241101"/>
                           <component>
                              <section ID="s25">
                                 <id root="ce6b6890-610d-4362-9f66-a74bbb98ea27"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hypoglycemia</content>
                                    </paragraph>
                                    <paragraph>
                                       <linkHtml href="#t2">Table 2</linkHtml> summarizes the incidence of hypoglycemic events in the placebo-controlled trials.
</paragraph>
                                    <table ID="t2" width="100%">
                                       <caption>TableÂ 2: Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Adult Patients with TypeÂ 2 Diabetes Mellitus
</caption>
                                       <col width="32.320%" align="left"/>
                                       <col width="16.660%" align="left"/>
                                       <col width="16.680%" align="left"/>
                                       <col width="16.680%" align="left"/>
                                       <col width="17.660%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="5" align="left" valign="top">
                                                <paragraph styleCode="footnote">* Reflects the study treatment period. Data include events occurring during 4 weeks of treatment-free safety follow up. Events after introduction of a new glucose-lowering treatment are excluded.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="5" align="left" valign="top">
                                                <paragraph styleCode="footnote">** Episodes requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="5" align="left" valign="top"/>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Placebo<br/>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">%</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">MOUNJARO <br/>5Â mg</content>
                                                <br/>
                                                <content styleCode="bold">%</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">MOUNJARO <br/>10Â mg</content>
                                                <br/>
                                                <content styleCode="bold">%</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">MOUNJARO <br/>15Â mg</content>
                                                <br/>
                                                <content styleCode="bold">%</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Monotherapy
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â  (40 weeks)*
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">N=115
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">N=121
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">N=119
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">N=120
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Blood glucose &lt;54Â mg/dL
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Severe hypoglycemia**
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Add-on to Basal Insulin with or without Metformin
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â  (40 weeks)*
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">N=120
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">N=116
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">N=119
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">N=120
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Blood glucose &lt;54Â mg/dL
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">16
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Severe hypoglycemia**
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Hypoglycemia was more frequent when MOUNJARO was used in combination with a sulfonylurea <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s73">14</linkHtml>)]</content>. In a clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level &lt;54Â mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s26">
                                 <id root="4d0c8d8c-fe73-42fd-8f45-07b5da29fe62"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Heart Rate Increase</content>
                                    </paragraph>
                                    <paragraph>In the pool of placebo-controlled trials, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of â¥15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. The clinical relevance of heart rate increases is uncertain.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s27">
                                 <id root="606962f4-cbf4-4880-bb03-4359c43f356c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hypersensitivity Reactions</content>
                                    </paragraph>
                                    <paragraph>Hypersensitivity reactions have been reported with MOUNJARO in the pool of placebo-controlled trials, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of MOUNJARO-treated patients compared to 1.7% of placebo-treated patients.
</paragraph>
                                    <paragraph>In the pool of seven clinical trials<content styleCode="italics">,</content> hypersensitivity reactions occurred in 106/2,570 (4.1%) of MOUNJARO-treated patients with anti-tirzepatide antibodies and in 73/2,455 (3.0%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s70">12.6</linkHtml>)].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s28">
                                 <id root="55a11bb8-9082-4c20-b85e-371060287ee5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Injection Site Reactions</content>
                                    </paragraph>
                                    <paragraph>In the pool of placebo-controlled trials, injection site reactions were reported in 3.2% of MOUNJARO-treated patients compared to 0.4% of placebo-treated patients.
</paragraph>
                                    <paragraph>In the pool of seven clinical trials, injection site reactions occurred in 119/2,570 (4.6%) of MOUNJARO-treated patients with anti-tirzepatide antibodies and in 18/2,455 (0.7%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s70">12.6</linkHtml>)].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s29">
                                 <id root="9811cbc5-2799-4f20-8df0-3cb674b3ad21"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Acute Gallbladder Disease</content>
                                    </paragraph>
                                    <paragraph>In the pool of placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s29a">
                                 <id root="489e6d61-400a-4b29-a020-e2cdca9bcdc6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Dysesthesia</content>
                                    </paragraph>
                                    <paragraph>In the pool of placebo-controlled clinical trials, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo.  
</paragraph>
                                 </text>
                                 <effectiveTime value="20241101"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s29b">
                                 <id root="9318d747-650b-4df2-9ca5-520e8ebecb59"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Dysgeusia</content>
                                    </paragraph>
                                    <paragraph>In the pool of placebo-controlled clinical trials, dysgeusia was reported by 0.1% of MOUNJARO-treated patients and 0% of placebo-treated patients.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241101"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s30">
                           <id root="eb6a8628-03a6-4669-b55c-9feb9dc12843"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory Abnormalities</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Amylase and Lipase Increase</content>
                              </paragraph>
                              <paragraph>In the pool of placebo-controlled clinical trials, treatment with MOUNJARO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 33% to 38% and serum lipase concentrations of 31% to 42%. Placebo-treated patients had a mean increase from baseline in pancreatic amylase of 4% and no changes were observed in lipase. The clinical significance of elevations in lipase or amylase with MOUNJARO is unknown in the absence of other signs and symptoms of pancreatitis.
</paragraph>
                           </text>
                           <effectiveTime value="20230515"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="f9832b9e-f774-4f87-8c5f-2a135bc7ee83"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience
</title>
                     <text>
                        <paragraph>The following adverse reactions have been reported during post-approval use of MOUNJARO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity</content>: anaphylaxis, angioedema
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal</content>: ileus
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pulmonary</content>: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.
</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s32">
               <id root="cd216c65-5565-41a1-a7c2-7d0eaacb3142"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <effectiveTime value="20220513"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>MOUNJARO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (<linkHtml href="#s34">7.2</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s33">
                     <id root="61e6a9ef-44ab-42ae-b4b9-700a210d80f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin
</title>
                     <text>
                        <paragraph>When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s34">
                     <id root="d3ab62a7-c0c7-40c5-9dd1-53e81d1583b9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Oral Medications
</title>
                     <text>
                        <paragraph>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO.
</paragraph>
                        <paragraph>Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with MOUNJARO.
</paragraph>
                        <paragraph>Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO. Hormonal contraceptives that are not administered orally should not be affected <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s44">8.3</linkHtml>) and Clinical Pharmacology (<linkHtml href="#s54">12.2</linkHtml>, <linkHtml href="#s59">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s35">
               <id root="e814c021-eb49-4f75-8179-5a8bfb4b19a6"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics"/>
                              <content styleCode="italics">Pregnancy:</content> Based on animal study, may cause fetal harm. (<linkHtml href="#s36">8.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Females of Reproductive Potential:</content> Advise females using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation. (<linkHtml href="#s34">7.2</linkHtml>, <linkHtml href="#s44">8.3</linkHtml>, <linkHtml href="#s59">12.3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s36">
                     <id root="08cdec39-5c84-419b-8d5f-094ece331f97"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20220513"/>
                     <component>
                        <section ID="s37">
                           <id root="a6952d55-0537-4434-af6a-bf453e602547"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data with MOUNJARO use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy <content styleCode="italics">(see Clinical Considerations)</content>. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</paragraph>
                              <paragraph>In pregnant rats administered tirzepatide during organogenesis, fetal growth reductions and fetal abnormalities occurred at clinical exposure in maternal rats based on AUC. In rabbits administered tirzepatide during organogenesis, fetal growth reductions were observed at clinically relevant exposures based on AUC. These adverse embryo/fetal effects in animals coincided with pharmacological effects on maternal weight and food consumption <content styleCode="italics">(see Data)</content>.
</paragraph>
                              <paragraph>The estimated background risk of major birth defects is 6â10% in women with pre-gestational diabetes with an HbA1c &gt;7% and has been reported to be as high as 20â25% in women with an HbA1c &gt;10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2â4% and 15â20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s38">
                           <id root="fa77249c-df1a-413c-83ab-c4289f42984d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                           <component>
                              <section ID="s39">
                                 <id root="d63191d6-b24f-4833-9b18-fecab3eb4431"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s40">
                           <id root="f79c0999-727c-46a7-ac64-5f1f2408e22f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                           <component>
                              <section ID="s41">
                                 <id root="829f6384-9990-4781-9b48-4c5000af9e93"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5Â mg/kg tirzepatide (0.03-, 0.07-, and 0.5-fold the MRHD of 15Â mg once weekly based on AUC) during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5Â mg/kg. In pregnant rabbits given once weekly subcutaneous doses of 0.01, 0.03, or 0.1Â mg/kg tirzepatide (0.01-, 0.06-, and 0.2-fold the MRHD) during organogenesis, pharmacologically-mediated effects on the gastrointestinal system resulting in maternal mortality or abortion in a few rabbits occurred at all dose levels. Reduced fetal weights associated with decreased maternal food consumption and body weights were observed at 0.1Â mg/kg. In a pre- and post-natal study in rats administered subcutaneous doses of 0.02, 0.10, or 0.25 mg/kg tirzepatide twice weekly from implantation through lactation, F<sub>1</sub> pups from F<sub>0</sub> maternal rats given 0.25Â mg/kg tirzepatide had statistically significant lower mean body weight when compared to controls from post-natal day 7 through post-natal day 126 for males and post-natal day 56 for females.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s42">
                     <id root="497820f7-4534-4bb0-9854-3b89298db9ce"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20220513"/>
                     <component>
                        <section ID="s43">
                           <id root="b96e4c4b-5fec-4489-9c5b-a723a770e85e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of tirzepatide in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for MOUNJARO and any potential adverse effects on the breastfed infant from MOUNJARO or from the underlying maternal condition.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s44">
                     <id root="fffd8aae-69f7-4055-aebb-eef5af44a7de"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential
</title>
                     <effectiveTime value="20220513"/>
                     <component>
                        <section ID="s45">
                           <id root="2c98ddb5-d136-45a6-a773-182366bc9de7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <paragraph>Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s34">7.2</linkHtml>) and Clinical Pharmacology (<linkHtml href="#s54">12.2</linkHtml>, <linkHtml href="#s59">12.3</linkHtml>)].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s46">
                     <id root="994e1909-8113-45bc-b993-8e05969d8ec8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>Safety and effectiveness of MOUNJARO have not been established in pediatric patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="s47">
                     <id root="c5740758-9b67-41f5-8956-2f01896583b7"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>In the pool of seven clinical trials, 1539 (30.1%) MOUNJARO-treated patients were 65 years of age or older, and 212 (4.1%) MOUNJARO-treated patients were 75 years of age or older at baseline.
</paragraph>
                        <paragraph>No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s48">
                     <id root="b9aaac3d-1176-4b2f-8cbe-cf284021abf1"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment
</title>
                     <text>
                        <paragraph>No dosage adjustment of MOUNJARO is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no change in tirzepatide pharmacokinetics (PK) was observed <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s59">12.3</linkHtml>)]</content>. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe adverse gastrointestinal reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s49">
                     <id root="2b9b2ba6-cb60-4260-85f9-41e1a5dee029"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment
</title>
                     <text>
                        <paragraph>No dosage adjustment of MOUNJARO is recommended for patients with hepatic impairment. In a clinical pharmacology study in subjects with varying degrees of hepatic impairment, no change in tirzepatide PK was observed <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s59">12.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s50">
               <id root="422e8ae1-35a6-451f-915c-50cac146c038"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE
</title>
               <text>
                  <paragraph>In the event of an overdosage, contact Poison Control for latest recommendations. Appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms. A period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5 days.
</paragraph>
               </text>
               <effectiveTime value="20220513"/>
            </section>
         </component>
         <component>
            <section ID="s51">
               <id root="2834db85-1cd8-4310-b7a1-5b3cc32deccc"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C<sub>225</sub>H<sub>348</sub>N<sub>48</sub>O<sub>68</sub>.
</paragraph>
                  <paragraph>Structural formula:
</paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>MOUNJARO is a clear, colorless to slightly yellow, sterile, preservative-free solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5Â mL solution of 2.5Â mg, 5Â mg, 7.5Â mg, 10Â mg, 12.5Â mg, or 15Â mg of tirzepatide and the following excipients: sodium chloride (4.1Â mg), sodium phosphate dibasic heptahydrate (0.7Â mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. MOUNJARO has a pH of 6.5 â 7.5.
</paragraph>
               </text>
               <effectiveTime value="20241101"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-uspi-chem-struc.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s52">
               <id root="9b3848d7-f049-44b0-acc7-33254c5ef0f7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20241101"/>
               <component>
                  <section ID="s53">
                     <id root="1af53cc6-453d-4c1f-9a5e-90271220a609"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.
</paragraph>
                        <paragraph>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.
</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="s54">
                     <id root="cec7fbbf-7f9e-4c90-8740-cf8427c31bc5"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <text>
                        <paragraph>Tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients with typeÂ 2 diabetes mellitus.
</paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                     <component>
                        <section ID="s55">
                           <id root="d2831c41-8b6f-4030-821c-bab4844c32e0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">First and Second-Phase Insulin Secretion</content>
                              </paragraph>
                              <paragraph>Tirzepatide enhances the first- and second-phase insulin secretion. (<linkHtml href="#fig1">FigureÂ 1</linkHtml>)<br/>
                                 <br/>
                              </paragraph>
                              <paragraph ID="fig1" styleCode="MultiMediaCaption">
                                 <content styleCode="bold">Figure 1: Mean insulin concentration at 0-120 minutes during hyperglycemic clamp at baseline and Week 28</content>
                              </paragraph>
                              <renderMultiMedia ID="f02" referencedObject="mm02"/>
                           </text>
                           <effectiveTime value="20230728"/>
                        </section>
                     </component>
                     <component>
                        <observationMedia ID="mm02">
                           <text>Figure 1
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="moun-uspi-f1-v1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <section ID="s56">
                           <id root="86f12126-4f8b-46c9-a594-02166af1fc7f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Insulin Sensitivity</content>
                              </paragraph>
                              <paragraph>Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study after 28 weeks of treatment.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s57">
                           <id root="6286177b-86a4-4d94-adf5-daba2e88a4d2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Glucagon Secretion</content>
                              </paragraph>
                              <paragraph>Tirzepatide reduces fasting and postprandial glucagon concentrations. Tirzepatide 15Â mg reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43%, compared with no change for placebo after 28 weeks of treatment.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s58">
                           <id root="ede7b4c3-7b6b-4d88-9461-580ab7af9543"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Gastric Emptying</content>
                              </paragraph>
                              <paragraph>Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. Tirzepatide slows post-meal glucose absorption, reducing postprandial glucose.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s59">
                     <id root="a6c29c68-ace5-4dc1-889b-caccc26ee880"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <text>
                        <paragraph>The pharmacokinetics of tirzepatide is similar between healthy subjects and patients with typeÂ 2 diabetes mellitus. Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration. Tirzepatide exposure increases in a dose-proportional manner.
</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                     <component>
                        <section ID="s60">
                           <id root="60e437ba-95b1-4853-96ba-0f15e4b4eaef"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours. The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s61">
                           <id root="dd249c3b-f379-4f78-8e32-36a32a9308da"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The mean apparent steady-state volume of distribution of tirzepatide following subcutaneous administration in patients with typeÂ 2 diabetes mellitus is approximately 10.3Â L. Tirzepatide is highly bound to plasma albumin (99%).
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s62">
                           <id root="a3e81bf5-68de-4c0a-93d5-2545966c86bf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The apparent population mean clearance of tirzepatide is 0.061Â L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing.
</paragraph>
                           </text>
                           <effectiveTime value="20241101"/>
                           <component>
                              <section ID="s63">
                                 <id root="18f0fcdc-9a37-4f78-a847-c9efc3ab338d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid and amide hydrolysis.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241101"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s64">
                                 <id root="aa3c08ba-7076-45e4-a328-272a2b321e67"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s65">
                           <id root="76d2cf18-f503-4541-b42b-79ab209bda68"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>The intrinsic factors of age, gender, race, ethnicity, or body weight do not have a clinically relevant effect on the PK of tirzepatide.
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                           <component>
                              <section ID="s66">
                                 <id root="83afe39d-c6ba-4f05-aac7-6954b3cb76d2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Renal impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5Â mg dose was evaluated in patients with different degrees of renal impairment (mild, moderate, severe, ESRD) compared with subjects with normal renal function. This was also shown for patients with both typeÂ 2 diabetes mellitus and renal impairment based on data from clinical studies <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s48">8.6</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s67">
                                 <id root="315307d2-a106-4ff9-91be-0b07a35b5911"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Hepatic impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5Â mg dose was evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) compared with subjects with normal hepatic function <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s49">8.7</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s68">
                           <id root="2ae94c62-69d3-4a54-8245-ee5e350bcbf8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                           <component>
                              <section ID="s69">
                                 <id root="6381b9c3-aa83-487b-8730-ce1dcd044e0a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Potential for Tirzepatide to Influence the Pharmacokinetics of Other Drugs</content>
                                    </paragraph>
                                    <paragraph>In vitro studies have shown low potential for tirzepatide to inhibit or induce CYP enzymes, and to inhibit drug transporters.
</paragraph>
                                    <paragraph>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s34">7.2</linkHtml>)]</content>.
</paragraph>
                                    <paragraph>The impact of tirzepatide on gastric emptying was greatest after a single dose of 5Â mg and diminished after subsequent doses.
</paragraph>
                                    <paragraph>Following a first dose of tirzepatide 5Â mg, acetaminophen maximum concentration (C<sub>max</sub>) was reduced by 50%, and the median peak plasma concentration (t<sub>max</sub>) occurred 1 hour later. After coadministration at week 4, there was no meaningful impact on acetaminophen C<sub>max</sub> and t<sub>max</sub>. Overall acetaminophen exposure (AUC<sub>0-24hr</sub>) was not influenced.
</paragraph>
                                    <paragraph>Following administration of a combined oral contraceptive (0.035Â mg ethinyl estradiol and 0.25Â mg norgestimate) in the presence of a single dose of tirzepatide 5Â mg, mean C<sub>max</sub> of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%,66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively. A delay in t<sub>max</sub> of 2.5 to 4.5Â hours was observed.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220513"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s70">
                     <id root="79c7471a-6658-45ca-ad0f-03e099dd1dc2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.6 Immunogenicity
</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the trials described below with the incidence of anti-drug antibodies in other trials.
</paragraph>
                        <paragraph>During the 40- to 104-week treatment periods with ADA sampling conducted up to 44 to 108 weeks in seven clinical trials in adults with type 2 diabetes mellitus <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s73">14</linkHtml>)],</content> 51% (2,570/5,025) of MOUNJARO-treated patients developed anti-tirzepatide antibodies. In these trials, anti-tirzepatide antibody formation in 34% and 14% of MOUNJARO-treated patients showed cross-reactivity to native GIP or native GLP-1, respectively.
</paragraph>
                        <paragraph>Of the 2,570 MOUNJARO-treated patients who developed anti-tirzepatide antibodies during the treatment periods in these seven trials, 2% and 2% developed neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors, respectively, and 0.9% and 0.4% developed neutralizing antibodies against native GIP or GLP-1, respectively.
</paragraph>
                        <paragraph>There was no identified clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of MOUNJARO. More MOUNJARO-treated patients who developed anti-tirzepatide antibodies experienced hypersensitivity reactions or injection site reactions than those who did not develop these antibodies <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s19">6.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s71">
               <id root="75d8521d-c972-472c-a068-656eb4adbb65"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20220513"/>
               <component>
                  <section ID="s72">
                     <id root="2eb3b2cc-4009-4d44-ad53-d7504c1b703d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5Â mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15Â mg once weekly based on AUC) administered by subcutaneous injection twice weekly. A statistically significant increase in thyroid C-cell adenomas was observed in males (â¥0.5Â mg/kg) and females (â¥0.15Â mg/kg), and a statistically significant increase in thyroid C-cell adenomas and carcinomas combined was observed in males and females at all doses examined. In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10Â mg/kg administered by subcutaneous injection twice weekly was not tumorigenic.
</paragraph>
                        <paragraph>Tirzepatide was not genotoxic in a rat bone marrow micronucleus assay.
</paragraph>
                        <paragraph>In fertility and early embryonic development studies, male and female rats were administered twice weekly subcutaneous doses of 0.5, 1.5, or 3Â mg/kg (0.3-, 1-, and 2-fold and 0.3-, 0.9-, and 2-fold, respectively, the MRHD of 15Â mg once weekly based on AUC). No effects of tirzepatide were observed on sperm morphology, mating, fertility, and conception. In female rats, an increase in the number of females with prolonged diestrus and a decrease in the mean number of corpora lutea resulting in a decrease in the mean number of implantation sites and viable embryos was observed at all dose levels. These effects were considered secondary to the pharmacological effects of tirzepatide on food consumption and body weight.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s73">
               <id root="53273f1d-601e-40f4-8509-8be9c7882134"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <effectiveTime value="20230728"/>
               <component>
                  <section ID="s74">
                     <id root="6f24b527-c432-485f-90f3-e7624c1e5b4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Overview of Clinical Studies
</title>
                     <text>
                        <paragraph>The effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus was established in five trials. In these trials, MOUNJARO was studied as monotherapy (SURPASS-1); as an add-on to metformin, sulfonylureas, and/or sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) (SURPASS-2, -3, and -4); and in combination with basal insulin with or without metformin (SURPASS-5). In these trials, MOUNJARO (5Â mg, 10Â mg, and 15Â mg given subcutaneously once weekly) was compared with placebo, semaglutide 1Â mg, insulin degludec, and/or insulin glargine.
</paragraph>
                        <paragraph>In adult patients with typeÂ 2 diabetes mellitus, treatment with MOUNJARO produced a statistically significant reduction from baseline in HbA1c compared to placebo. The effectiveness of MOUNJARO was not impacted by age, gender, race, ethnicity, region, or by baseline BMI, HbA1c, diabetes duration, or renal function.
</paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
               <component>
                  <section ID="s75">
                     <id root="3ed748c2-5978-4429-836a-2853da9df860"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Monotherapy Use of MOUNJARO in Adult Patients with TypeÂ 2 Diabetes Mellitus
</title>
                     <text>
                        <paragraph>SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with typeÂ 2 diabetes mellitus with inadequate glycemic control with diet and exercise to MOUNJARO 5Â mg, MOUNJARO 10Â mg, MOUNJARO 15Â mg, or placebo once weekly.
</paragraph>
                        <paragraph>Patients had a mean age of 54 years, and 52% were men. The mean duration of typeÂ 2 diabetes mellitus was 4.7 years, and the mean BMI was 32Â kg/m<sup>2</sup>. Overall, 36% were White, 35% were Asian, 25% were American Indians/Alaska Natives, and 5% were Black or African American; 43% identified as Hispanic or Latino ethnicity.
</paragraph>
                        <paragraph>Monotherapy with MOUNJARO 5Â mg, 10Â mg and 15Â mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see <linkHtml href="#t3">TableÂ 3</linkHtml>).
</paragraph>
                        <table ID="t3" width="100%">
                           <caption>TableÂ 3: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with TypeÂ 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise
</caption>
                           <col width="28.374%" align="left"/>
                           <col width="18.836%" align="left"/>
                           <col width="17.596%" align="left"/>
                           <col width="17.596%" align="left"/>
                           <col width="17.596%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 25%, 2%, 3%, and 2% of patients randomized to placebo, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. At Week 40 the HbA1c data were missing for 12%, 6%, 7%, and 14% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>c</sup> p&lt;0.001 (two-sided) for superiority vs. placebo, adjusted for multiplicity.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>d</sup> Analyzed using logistic regression adjusted for baseline value and other stratification factors.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">MOUNJARO<br/>5Â mg</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">MOUNJARO<br/>10Â mg</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">MOUNJARO<br/>15Â mg</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Modified Intent-to-Treat (mITT) Population (N)<sup>a</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">113
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">121
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">121
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">120
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8.1
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8.0
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7.9
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7.9
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-0.1
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.8
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.7
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.7
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from placebo<sup>b</sup> (95% CI)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.7<sup>c
</sup>
                                    <br/>(-2.0, -1.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.6<sup>c
</sup>
                                    <br/>(-1.9, -1.3)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.6<sup>c
</sup>
                                    <br/>(-1.9, -1.3)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Patients (%) achieving HbA1c &lt;7%<sup>d</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">82<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">85<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">78<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fasting Serum Glucose (mg/dL)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">155
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">154
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">153
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">154
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-40
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-40
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-39
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from <br/>Â  Â  Â placebo<sup>b</sup> (95% CI)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-43<sup>c</sup>
                                    <br/>(-55, -32)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-43<sup>c</sup>
                                    <br/>(-55, -32)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-42<sup>c</sup>
                                    <br/>(-54, -30)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body Weight (kg)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">84.5
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">87.0
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">86.2
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">85.5
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.0
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-6.3
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-7.0
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-7.8
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from <br/>Â  Â  Â placebo<sup>b</sup> (95% CI)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-5.3<sup>c</sup>
                                    <br/>(-6.8, -3.9)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-6.0<sup>c</sup>
                                    <br/>(-7.4, -4.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-6.8<sup>c</sup>
                                    <br/>(-8.3, -5.4)
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s76">
                     <id root="bc84ddb7-151c-4c3a-ad30-ec48591453f0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 MOUNJARO Use in Combination with Metformin, Sulfonylureas, and/or SGLT2 Inhibitors in Adult Patients with TypeÂ 2 Diabetes Mellitus
</title>
                     <effectiveTime value="20230728"/>
                     <component>
                        <section ID="s77">
                           <id root="2a6801e5-f0de-436c-98db-dca4efe91440"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-on to metformin</content>
                              </paragraph>
                              <paragraph>SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1879 adult patients with typeÂ 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of MOUNJARO 5Â mg, MOUNJARO 10Â mg, or MOUNJARO 15Â mg once weekly or subcutaneous semaglutide 1Â mg once weekly.
</paragraph>
                              <paragraph>Patients had a mean age of 57 years and 47% were men. The mean duration of typeÂ 2 diabetes mellitus was 8.6 years, and the mean BMI was 34Â kg/m<sup>2</sup>. Overall, 83% were White, 4% were Black or African American, and 1% were Asian; 70% identified as Hispanic or Latino ethnicity.
</paragraph>
                              <paragraph>Treatment with MOUNJARO 10Â mg and 15Â mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with semaglutide 1Â mg once weekly (see <linkHtml href="#t4">TableÂ 4</linkHtml> and <linkHtml href="#fig2">Figure 2</linkHtml>).
</paragraph>
                              <table ID="t4" width="100%">
                                 <caption>TableÂ 4: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1Â mg in Adult Patients with TypeÂ 2 Diabetes Mellitus Added to Metformin
</caption>
                                 <col width="43.160%" align="left"/>
                                 <col width="13.700%" align="left"/>
                                 <col width="13.500%" align="left"/>
                                 <col width="14.820%" align="left"/>
                                 <col width="14.820%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 3%, 2%, 1%, and 1% of patients randomized to semaglutide 1Â mg, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. At Week 40 the HbA1c endpoint was missing for 5%, 4%, 5%, and 5% of patients randomized to semaglutide 1Â mg, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. Missing Week 40 data were imputed using multiple imputation with retrieved dropout.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> p&lt;0.05 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> p&lt;0.001 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>e</sup> Analyzed using logistic regression adjusted for baseline value and other stratification factors.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>f</sup> p&lt;0.01 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Semaglutide <br/>1Â mg</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>5Â mg</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>10Â mg</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>15Â mg</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Modified Intent-to-Treat (mITT) Population (N)<content styleCode="bold">
                                             <sup>a</sup>
                                          </content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">468
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">470
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">469
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">469
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.3
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-1.9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.3
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from semaglutide<sup>b</sup> (95% CI)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.2<sup>c</sup>
                                          <br/>(-0.3, -0.0)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.4<sup>d
</sup>
                                          <br/>(-0.5, -0.3)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.5<sup>d</sup>
                                          <br/>(-0.6, -0.3)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Patients (%) achieving HbA1c &lt;7%<sup>e</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">79
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">82
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">86<sup>f</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">86<sup>f</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fasting Serum Glucose (mg/dL)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">171
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">174
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">174
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">172
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-49
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-55
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-59
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-60
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body Weight (kg)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">93.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">92.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">94.8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">93.8
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-5.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-7.6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-9.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-11.2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from semaglutide<sup>b</sup> (95% CI)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-1.9<sup>c
</sup>
                                          <br/>(-2.8, -1.0)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-3.6<sup>d
</sup>
                                          <br/>(-4.5, -2.7)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-5.5<sup>d</sup>
                                          <br/>(-6.4, -4.6)
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph ID="fig2" styleCode="MultiMediaCaption">
                                 <content styleCode="bold">FigureÂ 2. Mean HbA1c (%) Over Time - Baseline to Week 40</content>
                              </paragraph>
                              <renderMultiMedia ID="f03" referencedObject="mm03"/>
                              <table width="100%" styleCode="Noautorules">
                                 <col width="15.599%" align="left"/>
                                 <col width="5.053%" align="left"/>
                                 <col width="6.538%" align="left"/>
                                 <col width="6.538%" align="left"/>
                                 <col width="6.538%" align="left"/>
                                 <col width="6.538%" align="left"/>
                                 <col width="6.538%" align="left"/>
                                 <col width="6.538%" align="left"/>
                                 <col width="6.538%" align="left"/>
                                 <col width="11.276%" align="left"/>
                                 <col width="6.615%" align="left"/>
                                 <col width="5.784%" align="left"/>
                                 <col width="9.907%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="right" valign="top">
                                          <content styleCode="bold">NumberÂ ofÂ patients</content>
                                       </td>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="right" valign="top">
                                          <content styleCode="bold">MOUNJAROÂ 5mg</content>
                                       </td>
                                       <td align="right" valign="top">470
</td>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top">451
</td>
                                       <td align="right" valign="top">470
</td>
                                       <td align="right" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="right" valign="top">
                                          <content styleCode="bold">MOUNJAROÂ 10mg</content>
                                       </td>
                                       <td align="right" valign="top">469
</td>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top">445
</td>
                                       <td align="right" valign="top">469
</td>
                                       <td align="right" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="right" valign="top">
                                          <content styleCode="bold">MOUNJAROÂ 15mg</content>
                                       </td>
                                       <td align="right" valign="top">469
</td>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top">447
</td>
                                       <td align="right" valign="top">469
</td>
                                       <td align="right" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="right" valign="top">
                                          <content styleCode="bold">SemaglutideÂ 1mg</content>
                                       </td>
                                       <td align="right" valign="top">468
</td>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top"/>
                                       <td align="right" valign="top">443
</td>
                                       <td align="right" valign="top">468
</td>
                                       <td align="right" valign="top"/>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Note: Displayed results are from modified Intent-to-Treat Full Analysis Set. (1) Observed mean value from Week 0 to Week 40, and (2) least-squares mean Â± standard error at Week 40 multiple imputation (MI).
</paragraph>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <observationMedia ID="mm03">
                           <text>Figure 2
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="moun-uspi-f2-v1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <section ID="s78">
                           <id root="455cf2f8-bf2b-4d26-9d9e-a7bbf33d1fae"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-on to metformin with or without SGLT2 inhibitor</content>
                              </paragraph>
                              <paragraph>SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1444 adult patients with typeÂ 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of MOUNJARO 5Â mg, MOUNJARO 10Â mg, MOUNJARO 15Â mg once weekly, or insulin degludec 100Â units/mL once daily. In this trial, 32% of patients were on SGLT2 inhibitor. Insulin degludec was initiated at 10Â units once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 26% of patients randomized to insulin degludec achieved the fasting serum glucose target of &lt;90Â mg/dL, and the mean daily insulin degludec dose was 49 U (0.5Â U per kilogram).
</paragraph>
                              <paragraph>Patients had a mean age of 57 years, and 56% were men. The mean duration of typeÂ 2 diabetes mellitus was 8.4 years, and the mean baseline BMI was 34Â kg/m<sup>2</sup>. Overall, 91% were White, 3% were Black or African American, and 5% were Asian; 29% identified as Hispanic or Latino ethnicity.
</paragraph>
                              <paragraph>Treatment with MOUNJARO 10Â mg and 15Â mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with daily insulin degludec (see <linkHtml href="#t5">TableÂ 5</linkHtml>).
</paragraph>
                              <table ID="t5" width="100%">
                                 <caption>Table 5: Results at Week 52 in a Trial of MOUNJARO versus Insulin Degludec in Adult Patients with TypeÂ 2 Diabetes Mellitus Added to Metformin with or without SGLT2 Inhibitor
</caption>
                                 <col width="40.528%" align="left"/>
                                 <col width="14.883%" align="left"/>
                                 <col width="14.863%" align="left"/>
                                 <col width="14.863%" align="left"/>
                                 <col width="14.863%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%,1%, 1%, and 2% of patients randomized to insulin degludec, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 6%, 10%, and 5% of patients randomized to insulin degludec, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> p&lt;0.001 (two-sided) for superiority vs. insulin degludec, adjusted for multiplicity.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> Analyzed using logistic regression adjusted for baseline value and other stratification factors.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Insulin Degludec</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>5Â mg</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>10Â mg</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>15Â mg</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Modified Intent-to-Treat (mITT)<sup>a</sup> Population (N)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">359
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">358
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">360
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">358
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 52<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-1.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-1.9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from insulin degludec<sup>b</sup> (95% CI)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.6<sup>c
</sup>
                                          <br/>(-0.7, -0.5)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.8<sup>c
</sup>
                                          <br/>(-0.9, -0.6)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.9<sup>c
</sup>
                                          <br/>(-1.0, -0.7)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Patients (%) achieving HbA1c &lt;7%<sup>d</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">58
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">79<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">82<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">83<sup>c</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fasting Serum Glucose (mg/dL)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">167
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">172
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">170
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">168
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 52<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-51
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-47
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-50
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-54
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body Weight (kg)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">94.0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">94.4
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">93.8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">94.9
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 52<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-7.0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-9.6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-11.3
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from insulin degludec<sup>b</sup> (95% CI)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-8.9<sup>c
</sup>
                                          <br/>(-10.0, -7.8)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-11.5<sup>c
</sup>
                                          <br/>(-12.6, -10.4)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-13.2<sup>c
</sup>
                                          <br/>(-14.3, -12.1)
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20220513"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s79">
                           <id root="f8f3490b-8a3d-49bc-8c14-9606f0665737"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea or SGLT-2 inhibitor)</content>
                              </paragraph>
                              <paragraph>SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with typeÂ 2 diabetes mellitus with increased cardiovascular risk to MOUNJARO 5Â mg, MOUNJARO 10Â mg, MOUNJARO 15Â mg once weekly, or insulin glargine 100Â units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%).
</paragraph>
                              <paragraph>Patients had a mean age of 64 years, and 63% were men. The mean duration of typeÂ 2 diabetes mellitus was 11.8 years, and the mean baseline BMI was 33 kg/m<sup>2</sup>. Overall, 82% were White, 4% were Black or African American, and 4% were Asian; 48% identified as Hispanic or Latino ethnicity. Across all treatment groups, 87% had a history of cardiovascular disease. At baseline, eGFR was â¥90Â mL/min/1.73Â m<sup>2</sup> in 43%, 60 to 90Â mL/min/1.73Â m<sup>2</sup> in 40%, 45 to 60Â mL/min/1.73Â m<sup>2</sup> in 10%, and 30 to 45Â mL/min/1.73Â m<sup>2</sup> in 6% of patients.
</paragraph>
                              <paragraph>Insulin glargine was initiated at 10Â U once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 30% of patients randomized to insulin glargine achieved the fasting serum glucose target of &lt;100Â mg/dL, and the mean daily insulin glargine dose was 44Â U (0.5Â U per kilogram).
</paragraph>
                              <paragraph>Treatment with MOUNJARO 10Â mg and 15Â mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with insulin glargine once daily (see <linkHtml href="#t6">TableÂ 6</linkHtml>).
</paragraph>
                              <table ID="t6" width="100%">
                                 <caption>TableÂ 6: Results at Week 52 in a Trial of MOUNJARO versus Insulin Glargine in Adult Patients with TypeÂ 2 Diabetes Mellitus Added to Metformin and/or Sulfonylurea and/or SGLT2 Inhibitor
</caption>
                                 <col width="43.691%" align="left"/>
                                 <col width="13.777%" align="left"/>
                                 <col width="14.177%" align="left"/>
                                 <col width="14.177%" align="left"/>
                                 <col width="14.177%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%, 0%, 0%, and 1% of patients randomized to insulin glargine, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 9%, 6%, and 4% of patients randomized to insulin glargine, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> p&lt;0.001 (two-sided) for superiority vs. insulin glargine, adjusted for multiplicity.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> Analyzed using logistic regression adjusted for baseline value and other stratification factors.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Insulin Glargine</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>5Â mg</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>10Â mg</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">MOUNJARO<br/>15Â mg</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Modified Intent-to-Treat (mITT) Population (N)<sup>a</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">998
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">328
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">326
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">337
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8.5
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 52<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-1.4
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.4
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from insulin glargine<sup>b</sup> (95% CI)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.7<sup>c
</sup>
                                          <br/>(-0.9, -0.6)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-0.9<sup>c
</sup>
                                          <br/>(-1.1, -0.8)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-1.0<sup>c
</sup>
                                          <br/>(-1.2, -0.9)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Patients (%) achieving HbA1c &lt;7%<sup>d</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">49
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">75<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">83<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">85<sup>c</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fasting Serum Glucose (mg/dL)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">168
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">172
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">176
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">174
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 52<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-49
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-44
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-50
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-55
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body Weight (kg)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">90.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">90.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">90.6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">90.0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 52<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-6.4
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-8.9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-10.6
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from insulin glargine<sup>b</sup> (95% CI)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-8.1<sup>c
</sup>
                                          <br/>(-8.9, -7.3)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-10.6<sup>c</sup>
                                          <br/>(-11.4, -9.8)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-12.2<sup>c
</sup>
                                          <br/>(-13.0, -11.5)
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20230728"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s80">
                     <id root="b01bbc0e-2fdf-4d6f-ac68-0976e86b98d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 MOUNJARO Use in Combination with Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus
</title>
                     <text>
                        <paragraph>SURPASS-5 (NCT04039503) was a 40-week double-blind trial that randomized 475 patients with typeÂ 2 diabetes mellitus with inadequate glycemic control on insulin glargine 100Â units/mL, with or without metformin, to MOUNJARO 5Â mg, MOUNJARO 10Â mg, MOUNJARO 15Â mg once weekly, or placebo. The dose of background insulin glargine was adjusted using a treat-to-target algorithm based on self-measured fasting blood glucose values, targeting &lt;100Â mg/dL.
</paragraph>
                        <paragraph>Patients had a mean age of 61 years, and 56% were men. The mean duration of typeÂ 2 diabetes mellitus was 13.3 years, and the mean baseline BMI was 33Â kg/m<sup>2</sup>. Overall, 80% were White, 1% were Black or African American, and 18% were Asian; 5% identified as Hispanic or Latino ethnicity.
</paragraph>
                        <paragraph>The mean dose of insulin glargine at baseline was 34, 32, 35, and 33Â units/day for patients receiving MOUNJARO 5Â mg, 10Â mg, 15Â mg, and placebo, respectively. At randomization, the initial insulin glargine dose in patients with HbA1c â¤8.0% was reduced by 20%. At week 40, mean dose of insulin glargine was 38, 36, 29, and 59Â units/day for patients receiving MOUNJARO 5Â mg, 10Â mg, 15Â mg, and placebo, respectively.
</paragraph>
                        <paragraph>Treatment with MOUNJARO 5Â mg once weekly, 10Â mg once weekly and 15Â mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see <linkHtml href="#t7">TableÂ 7</linkHtml>).
</paragraph>
                        <table ID="t7" width="100%">
                           <caption>Table 7: Results at Week 40 in a Trial of MOUNJARO Added to Basal Insulin with or without Metformin in Adult Patients with TypeÂ 2 Diabetes Mellitus
</caption>
                           <col width="44.449%" align="left"/>
                           <col width="13.183%" align="left"/>
                           <col width="14.123%" align="left"/>
                           <col width="14.123%" align="left"/>
                           <col width="14.123%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 4%, 1%, 0%, and 1% of patients randomized to placebo, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. At Week 40 the HbA1c endpoint was missing for 2%, 6%, 3%, and 7% of patients randomized to placebo, MOUNJARO 5Â mg, 10Â mg, and 15Â mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>c</sup> p&lt;0.001 (two-sided) for superiority vs. placebo, adjusted for multiplicity.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>d</sup> Analyzed using logistic regression adjusted for baseline value and other stratification factors.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">MOUNJARO<br/>5Â mg</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">MOUNJARO<br/>10Â mg</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">MOUNJARO<br/>15Â mg</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Modified Intent-to-Treat (mITT) Population (N)<sup>a</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">119
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">116
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">118
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">118
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8.4
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8.3
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8.4
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8.2
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-0.9
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-2.1
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-2.4
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-2.3
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from placebo<sup>b</sup> (95% CI)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.2<sup>c</sup>
                                    <br/>(-1.5, -1.0)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.5<sup>c</sup>
                                    <br/>(-1.8, -1.3)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.5<sup>c</sup>
                                    <br/>(-1.7, -1.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Patients (%) achieving HbA1c &lt;7%<sup>d</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">35
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">87<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">90<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">85<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fasting Serum Glucose (mg/dL)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">164
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">163
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">163
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">160
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-39
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-58
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-64
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-63
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from placebo<sup>b</sup> (95% CI)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-19<sup>c
</sup>
                                    <br/>(-27, -11)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-25<sup>c</sup>
                                    <br/>(-32, -17)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-23<sup>c</sup>
                                    <br/>(-31, -16)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body Weight (kg)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline (mean)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">94.2
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">95.8
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">94.6
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">96.0
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change at Week 40<sup>b</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.6
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-5.4
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-7.5
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-8.8
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from placebo<sup>b</sup> (95% CI)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">--
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-7.1<sup>c</sup>
                                    <br/>(-8.7, -5.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-9.1<sup>c</sup>
                                    <br/>(-10.7, -7.5)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-10.5<sup>c</sup>
                                    <br/>(-12.1, -8.8)
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s81">
               <id root="f437820e-cbaf-4c20-b274-f8c28306d5c4"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <effectiveTime value="20240516"/>
               <component>
                  <section ID="s82">
                     <id root="339b5fda-9ed1-41eb-9fd1-1be6fd2b3b1b"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied
</title>
                     <text>
                        <paragraph>MOUNJARO is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens or 1 single-dose vial as follows:
</paragraph>
                        <table width="100%">
                           <col width="30.823%" align="left"/>
                           <col width="37.054%" align="left"/>
                           <col width="32.123%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Total Strength per Total Volume</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold underline">Pen </content>
                                    <content styleCode="bold">NDC</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold underline">Vial </content>
                                    <content styleCode="bold">NDC</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">2.5Â mg/0.5Â mL
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-1506-80
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-1152-01
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">5Â mg/0.5Â mL
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-1495-80
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-1243-01
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">7.5Â mg/0.5Â mL
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-1484-80
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-2214-01
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">10Â mg/0.5 mL
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-1471-80
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-2340-01
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">12.5Â mg/0.5Â mL
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-1460-80
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-2423-01
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">15Â mg/0.5Â mL
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-1457-80
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">0002-3002-01
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240516"/>
                  </section>
               </component>
               <component>
                  <section ID="s83">
                     <id root="82059d87-c0c0-4ea5-a9a2-621e068e853e"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Store MOUNJARO in a refrigerator at 2Â°C to 8Â°C (36Â°F to 46Â°F).
</item>
                           <item>If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30ÂºC (86ÂºF) for up to 21 days.
</item>
                           <item>Do not freeze MOUNJARO. Do not use MOUNJARO if frozen.
</item>
                           <item>Store MOUNJARO in the original carton to protect from light.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s84">
               <id root="addffd52-42af-4ebe-ba54-f500ba268e7e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling <content styleCode="italics">(Medication Guide and Instructions for Use).</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241101"/>
               <component>
                  <section ID="s85">
                     <id root="ec08f5bb-ab28-48ed-b164-93f8f35775c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk of Thyroid C-Cell Tumors</content>
                        </paragraph>
                        <paragraph>Inform patients that MOUNJARO causes thyroid C-cell tumors in rats and that the human relevance of this finding has not been determined. Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, persistent hoarseness, dysphagia, or dyspnea) to their healthcare provider <content styleCode="italics">[see <linkHtml href="#s1">Boxed Warning</linkHtml> and Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s86">
                     <id root="b78ed1db-d2d8-490b-8608-dd723d368ee2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pancreatitis</content>
                        </paragraph>
                        <paragraph>Inform patients of the potential risk for pancreatitis. Instruct patients to discontinue MOUNJARO promptly and contact their healthcare provider if pancreatitis is suspected (severe abdominal pain that may radiate to the back, and which may or may not be accompanied by vomiting) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s87">
                     <id root="154730b7-76c0-472b-809d-ef6af6cffe72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin</content>
                        </paragraph>
                        <paragraph>Inform patients that the risk of hypoglycemia is increased when MOUNJARO is used with an insulin secretagogue (such as a sulfonylurea) or insulin. Educate patients on the signs and symptoms of hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s88">
                     <id root="18106b54-a68a-4a8b-a43c-c6d8e566d457"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that serious hypersensitivity reactions have been reported with use of MOUNJARO. Advise patients on the symptoms of hypersensitivity reactions and instruct them to stop taking MOUNJARO and seek medical advice promptly if such symptoms occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20230515"/>
                  </section>
               </component>
               <component>
                  <section ID="s89">
                     <id root="078c80f0-e925-4109-8362-33d29a9f69a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Acute Kidney Injury</content>
                        </paragraph>
                        <paragraph>Advise patients treated with MOUNJARO of the potential risk of dehydration due to gastrointestinal adverse reactions and take precautions to avoid fluid depletion. Inform patients of the potential risk for worsening renal function and explain the associated signs and symptoms of renal impairment, as well as the possibility of dialysis as a medical intervention if renal failure occurs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.5</linkHtml>]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s90">
                     <id root="7af30be3-6620-4cc7-b253-5374840b48a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Severe Gastrointestinal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients of the potential risk of severe gastrointestinal adverse reactions. Instruct patients to contact their healthcare provider if they have severe or persistent gastrointestinal symptoms <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.6</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s91">
                     <id root="a3ead2bb-3d12-493d-8653-9623f4fd03e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Diabetic Retinopathy Complications</content>
                        </paragraph>
                        <paragraph>Inform patients to contact their healthcare provider if changes in vision are experienced during treatment with MOUNJARO <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.7</linkHtml>]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s92">
                     <id root="37e6f8a4-813a-4b13-8227-688b1d876dd5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Acute Gallbladder Disease</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk of acute gallbladder disease. Instruct patients to contact their healthcare provider for appropriate clinical follow-up if gallbladder disease is suspected <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.8</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s92a">
                     <id root="9af18b17-e1a9-447c-b1ca-90a600a80f0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pulmonary Aspiration During General Anesthesia or Deep Sedation</content>
                        </paragraph>
                        <paragraph>Inform patients that MOUNJARO may cause their stomach to empty more slowly which may lead to complications with anesthesia or deep sedation during planned surgeries or procedures. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking MOUNJARO <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17a">5.9</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="s93">
                     <id root="09d09e99-731f-4b9e-a17a-52073ea8bb6e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise a pregnant woman of the potential risk to a fetus. Advise women to inform their healthcare provider if they are pregnant or intend to become pregnant <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s36">8.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s94">
                     <id root="45f52bae-db92-4f0b-aa14-d68073af5042"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s34">7.2</linkHtml>), Use in Specific Populations (<linkHtml href="#s44">8.3</linkHtml>), and Clinical Pharmacology (<linkHtml href="#s59">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220513"/>
                  </section>
               </component>
               <component>
                  <section ID="s94a">
                     <id root="83b07505-fff3-4764-b5cb-312737cc309e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <paragraph>Instruct patients how to prepare and administer the correct dose of MOUNJARO and assess their ability to inject subcutaneously to ensure the proper administration of MOUNJARO. Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1Â mL syringe capable of measuring a 0.5Â mL dose) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s6">2.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
               <component>
                  <section ID="s95">
                     <id root="80801123-0ce3-48a2-858a-eba1512dfe51"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Missed Doses</content>
                        </paragraph>
                        <paragraph>Inform patients if a dose is missed, it should be administered as soon as possible within 4 days after the missed dose. If more than 4 days have passed, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day. In each case, inform patients to resume their regular once weekly dosing schedule <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s5">2.1</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA<br/>
                           </content>Copyright Â© 2022, 2024, Eli Lilly and Company. All rights reserved.
</paragraph>
                        <paragraph>MOU-0004-USPI-20241101
</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s96">
               <id root="206fb57f-d46f-4914-9859-fc6c470326b0"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>Mounjaro Medication Guide</title>
               <text>
                  <table width="100%">
                     <col width="33.325%" align="left"/>
                     <col width="16.675%" align="left"/>
                     <col width="16.675%" align="left"/>
                     <col width="33.325%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="4" align="left" valign="top">
                              <paragraph styleCode="footnote">This Medication Guide has been approved by the U.S. Food and Drug Administration Approved: November 2024
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="4" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Medication Guide</content>
                              <br/>
                              <content styleCode="bold">MOUNJARO<sup>Â®</sup> [mown-JAHR-OH]</content>
                              <br/>
                              <content styleCode="bold">(tirzepatide)</content>
                              <br/>
                              <content styleCode="bold">injection, for subcutaneous use</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph ID="p03">
                                 <content styleCode="bold">What is the most important information I should know about MOUNJARO?</content>
                                 <br/>
                                 <content styleCode="bold">MOUNJARO may cause serious side effects, including:</content>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Possible thyroid tumors, including cancer.</content> Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats, MOUNJARO and medicines that work like MOUNJARO caused thyroid tumors, including thyroid cancer. It is not known if MOUNJARO will cause thyroid tumors, or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.
</item>
                                 <item>Do not use MOUNJARO if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome typeÂ 2 (MENÂ 2).
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What is MOUNJARO?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>MOUNJARO is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with typeÂ 2 diabetes mellitus.
</item>
                                 <item>It is not known if MOUNJARO can be used in people who have had pancreatitis.
</item>
                                 <item>MOUNJARO is not for use in people with typeÂ 1 diabetes.
</item>
                                 <item>It is not known if MOUNJARO is safe and effective for use in children under 18 years of age.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Do not use MOUNJARO if:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome typeÂ 2 (MENÂ 2).
</item>
                                 <item>you have had a serious allergic reaction to tirzepatide or any of the ingredients in MOUNJARO. See the end of this Medication Guide for a complete list of ingredients in MOUNJARO.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before using MOUNJARO, tell your healthcare provider about all of your medical conditions</content>, <content styleCode="bold">including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have or have had problems with your pancreas or kidneys.
</item>
                                 <item>have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food.
</item>
                                 <item>have a history of diabetic retinopathy.
</item>
                                 <item>are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).
</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if MOUNJARO will harm your unborn baby. Tell your healthcare provider if you become pregnant while using MOUNJARO.
											
												<list listType="unordered" styleCode="Circle">
                                       <item>
                                          <content styleCode="bold">Birth control pills by mouth may not work as well while using MOUNJARO</content>. If you take birth control pills by mouth, your healthcare provider may recommend another type of birth control for 4 weeks after you start MOUNJARO and for 4 weeks after each increase in your dose of MOUNJARO. Talk to your healthcare provider about birth control methods that may be right for you while using MOUNJARO.<br/>
                                          <br/>
                                       </item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if MOUNJARO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while using MOUNJARO.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. MOUNJARO may affect the way some medicines work, and some medicines may affect the way MOUNJARO works.<br/>
                              <content styleCode="bold">Before using MOUNJARO, tell your healthcare provider if you are taking other medicines to treat diabetes including insulin or sulfonylureas which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar and how to manage it.</content>
                              <br/>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">How should I use MOUNJARO?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read the <content styleCode="bold">Instructions for Use</content> that comes with MOUNJARO.
</item>
                                 <item>Use MOUNJARO exactly as your healthcare provider tells you to. A healthcare provider should show you how to prepare and inject your dose of MOUNJARO before injecting for the first time.
</item>
                                 <item>MOUNJARO is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
</item>
                                 <item>
                                    <content styleCode="bold">Use MOUNJARO 1 time each week, at any time of the day.</content>
                                 </item>
                                 <item>You may change the day of the week you use MOUNJARO as long as the time between the 2 doses is at least <content styleCode="bold">3</content> days (72 hours).
</item>
                                 <item>If you miss a dose of MOUNJARO, take the missed dose as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and take your next dose on the regularly scheduled day. <content styleCode="bold">Do not</content> take <content styleCode="bold">2</content> doses of MOUNJARO within <content styleCode="bold">3</content> days of each other.
</item>
                                 <item>MOUNJARO may be taken with or without food.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> mix insulin and MOUNJARO together in the same injection.
</item>
                                 <item>You may give an injection of MOUNJARO and insulin in the same body area (such as your stomach area), but not right next to each other.
</item>
                                 <item>Change (rotate) your injection site with each weekly injection. <content styleCode="bold">Do not</content> use the same site for each injection.
</item>
                                 <item>If you take too much MOUNJARO, call your healthcare provider.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of MOUNJARO?</content>
                              <br/>
                              <content styleCode="bold">MOUNJARO may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">â<linkHtml href="#p03">What is the most important information I should know about MOUNJARO?</linkHtml>â</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">inflammation of your pancreas (pancreatitis).</content> Stop using MOUNJARO and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
</item>
                                 <item>
                                    <content styleCode="bold">low blood sugar (hypoglycemia).</content> Your risk for getting low blood sugar may be higher if you use MOUNJARO with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. <content styleCode="bold">Signs and symptoms of low blood sugar may include:</content>
                                    <br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>dizziness or light-headedness
</item>
                                 <item>sweating
</item>
                                 <item>confusion or drowsiness
</item>
                                 <item>headache
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>blurred vision
</item>
                                 <item>slurred speech
</item>
                                 <item>shakiness
</item>
                                 <item>fast heartbeat
</item>
                              </list>
                           </td>
                           <td align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>anxiety, irritability, or mood changes
</item>
                                 <item>hunger
</item>
                                 <item>weakness
</item>
                                 <item>feeling jittery
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">serious allergic reactions.</content> Stop using MOUNJARO and get medical help right away if you have any symptoms of a serious allergic reaction including:<br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>swelling of your face, lips, tongue or throat
</item>
                                 <item>problems breathing or swallowing
</item>
                                 <item>severe rash or itching
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>fainting or feeling dizzy
</item>
                                 <item>very rapid heartbeat
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">kidney problems (kidney failure).</content> In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
</item>
                                 <item>
                                    <content styleCode="bold">severe stomach problems.</content> Stomach problems, sometimes severe, have been reported in people who use MOUNJARO. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
</item>
                                 <item>
                                    <content styleCode="bold">changes in vision.</content> Tell your healthcare provider if you have changes in vision during treatment with MOUNJARO.
</item>
                                 <item>
                                    <content styleCode="bold">gallbladder problems.</content> Gallbladder problems have happened in some people who use MOUNJARO. Tell your healthcare provider right away if you get symptoms of gallbladder problems which may include:<br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>pain in your upper stomach (abdomen)
</item>
                                 <item>fever
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>yellowing of skin or eyes (jaundice)
</item>
                                 <item>clay-colored stools
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).</content> MOUNJARO may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking MOUNJARO before you are scheduled to have surgery or other procedures. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of MOUNJARO include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>nausea
</item>
                                 <item>diarrhea
</item>
                                 <item>decreased appetite
</item>
                                 <item>vomiting
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>constipation
</item>
                                 <item>indigestion
</item>
                                 <item>stomach (abdominal) pain
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">Talk to your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of MOUNJARO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store MOUNJARO?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store MOUNJARO in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C). Store MOUNJARO in the original carton until use to protect it from light.
</item>
                                 <item>If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86Â°F (30Â°C) for up to 21 days.
</item>
                                 <item>Do not freeze MOUNJARO. Do not use MOUNJARO if frozen.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Keep MOUNJARO and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of MOUNJARO.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use MOUNJARO for a condition for which it was not prescribed. Do not give MOUNJARO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about MOUNJARO that is written for health professionals.
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in MOUNJARO?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> tirzepatide<br/>
                              <content styleCode="bold">Inactive ingredients:</content> sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH.<br/>MOUNJARO<sup>Â®</sup> is a registered trademark of Eli Lilly and Company.<br/>Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA<br/>Copyright Â© 2022, 2024, Eli Lilly and Company. All rights reserved.<br/>For more information, go to www.MOUNJARO.com or call 1-800-545-5979.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>MOU-0003-MG-20241101
</paragraph>
               </text>
               <effectiveTime value="20241101"/>
            </section>
         </component>
         <component>
            <section ID="s97">
               <id root="5bf98bc8-664e-4c05-ade1-3f13854ba92e"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Mounjaro Single-Dose Pen Instructions for Use</title>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="justify" valign="bottom">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              <br/>
                              <content styleCode="bold">MOUNJARO<sup>Â®</sup> (mown-JAHR-OH)</content>
                              <br/>
                              <content styleCode="bold">(tirzepatide)</content>
                              <br/>
                              <content styleCode="bold">injection, for subcutaneous use</content>
                              <br/>
                              <br/>
                              <renderMultiMedia ID="f04" referencedObject="mm04"/>
                              <br/>
                              <br/>
                              <br/>
                              <content styleCode="bold">2.5Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">5Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">7.5Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">10Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">12.5Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">15Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">use 1 time each week</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before injecting MOUNJARO</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read this Instructions for Use and the Medication Guide before using your MOUNJARO Pen and each time you get a refill.</content> There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
</paragraph>
                  <paragraph>Talk to your healthcare provider about how to inject MOUNJARO the right way.
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>MOUNJARO is a single-dose prefilled pen.
</item>
                     <item>MOUNJARO is used 1 time each week.
</item>
                     <item>Inject under the skin (subcutaneously) only.
</item>
                     <item>You or another person can inject into your stomach (abdomen) or thigh.
</item>
                     <item>Another person can inject into the back of your upper arm.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Guide to parts</content>
                  </paragraph>
                  <renderMultiMedia ID="f05" referencedObject="mm05"/>
                  <paragraph>
                     <content styleCode="bold">Preparing to inject MOUNJARO</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="14.133%" align="left"/>
                     <col width="10.833%" align="left"/>
                     <col width="75.033%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="3" align="left" valign="middle">
                              <content styleCode="bold">Remove the Pen</content> from the refrigerator.<br/>Leave the gray base cap on until you are ready to inject.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Check the Pen</content> label to make sure you have the right medicine and dose, and that it has not expired.<br/>
                              <br/>
                              <br/>
                              <content styleCode="bold">Inspect the Pen</content> to make sure that it is not damaged.
</td>
                           <td align="left" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f06" referencedObject="mm06"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="middle">Make sure the medicine:
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="middle">
                              <list listType="unordered" styleCode="Disc">
                                 <item>is not frozen
</item>
                                 <item>is not cloudy
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="middle">
                              <list listType="unordered" styleCode="Disc">
                                 <item>is colorless to slightly yellow
</item>
                                 <item>does not have particles
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="middle">
                              <content styleCode="bold">Wash your hands.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="15.850%" align="left"/>
                     <col width="84.150%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">Step</content>
                              <br/>
                              <content styleCode="bold">1</content>
                           </td>
                           <td align="left" valign="middle">
                              <content styleCode="bold">Choose your injection site</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f07" referencedObject="mm07"/>
                           </td>
                           <td align="left" valign="top">Your healthcare provider can help you choose the injection site that is best for you.<br/>
                              <br/>You or another person can inject the medicine in your stomach (abdomen) or thigh.
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f08" referencedObject="mm08"/>
                           </td>
                           <td align="left" valign="top">Another person should give you the injection in the back of your upper arm.<br/>Change (rotate) your injection site each week.<br/>You may use the same area of your body but be sure to choose a different injection site in that area.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="10.800%" align="left"/>
                     <col width="18.933%" align="left"/>
                     <col width="70.267%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">Step</content>
                              <br/>
                              <content styleCode="bold">2</content>
                           </td>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Pull off the gray base cap</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" rowspan="2" align="center" valign="top">
                              <renderMultiMedia ID="f09" referencedObject="mm09"/>
                           </td>
                           <td align="left" valign="top">Make sure the Pen is <content styleCode="bold">locked</content>.<br/>
                              <content styleCode="bold">Do not</content> unlock the Pen until you place the clear base on your skin and are ready to inject.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="bottom">
                              <content styleCode="bold">Pull</content> the gray base cap straight off and throw it away in your household trash.<br/>
                              <content styleCode="bold">Do not</content> put the gray base cap back on â this could damage the needle.<br/>
                              <content styleCode="bold">Do not</content> touch the needle.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="15.067%" align="left"/>
                     <col width="9.733%" align="left"/>
                     <col width="75.200%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">Step</content>
                              <br/>
                              <content styleCode="bold">3</content>
                           </td>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Place clear base on skin, then unlock</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top"/>
                           <td colspan="2" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f10" referencedObject="mm10"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Place</content> the clear base flat against your skin at the injection site.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f11" referencedObject="mm11"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Unlock</content> by turning the lock ring.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="10.800%" align="left"/>
                     <col width="10.000%" align="left"/>
                     <col width="79.200%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <paragraph ID="p02">
                                 <content styleCode="bold">Step</content>
                                 <br/>
                                 <content styleCode="bold">4</content>
                              </paragraph>
                           </td>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Press and hold up to 10 seconds</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f12" referencedObject="mm12"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Press and hold</content> the purple injection button for up to 10 seconds.<br/>
                              <content styleCode="bold">Listen</content> for:<br/>â¢ First click = injection started<br/>â¢ Second click = injection completed
</td>
                        </tr>
                        <tr>
                           <td colspan="2" rowspan="2" align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f13" referencedObject="mm13"/>
                           </td>
                           <td align="left" valign="middle">You will know your injection is complete when the gray plunger is visible.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="middle"/>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">After your injection, place the used Pen in a sharps container.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">See <content styleCode="bold">
                                 <linkHtml href="#p01">Disposing of your used Pen.</linkHtml>
                              </content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="62.550%" align="left"/>
                     <col width="37.450%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <paragraph ID="p01">
                                 <content styleCode="bold">Disposing of your used Pen</content>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Put your used Pen in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) Pens in your household trash.<br/>
                                    <br/>
                                 </item>
                                 <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered" styleCode="Disc">
                                       <item>
                                          <caption>-
</caption>made of a heavy-duty plastic,
</item>
                                       <item>
                                          <caption>-
</caption>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
</item>
                                       <item>
                                          <caption>-
</caption>upright and stable during use,
</item>
                                       <item>
                                          <caption>-
</caption>leak-resistant, and
</item>
                                       <item>
                                          <caption>-
</caption>properly labeled to warn of hazardous waste inside the container.
</item>
                                    </list>
                                    <br/>
                                 </item>
                                 <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.<br/>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> recycle your used sharps disposal container.
</item>
                              </list>
                           </td>
                           <td align="center" valign="top"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Storage and handling</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store your Pen in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C). <br/>
                        <br/>
                     </item>
                     <item>You may store your Pen at room temperature up to 86Â°F (30Â°C) for up to 21 days. <br/>
                        <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> freeze your Pen. If the Pen has been frozen, throw the Pen away and use a new Pen. <br/>
                        <br/>
                     </item>
                     <item>Store your Pen in the original carton to protect your Pen from light. <br/>
                        <br/>
                     </item>
                     <item>The Pen has glass parts. Handle it carefully. If you drop the Pen on a hard surface, <content styleCode="bold">do not</content> use it. Use a new Pen for your injection. <br/>
                        <br/>
                     </item>
                     <item>Keep your MOUNJARO Pen and all medicines out of the reach of children.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Commonly asked questions</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I see air bubbles in my Pen?</content>
                  </paragraph>
                  <paragraph>Air bubbles are normal.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if my Pen is not at room temperature?</content>
                  </paragraph>
                  <paragraph>It is not necessary to warm the Pen to room temperature.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I unlock the Pen and press the purple injection button before pulling off the gray base cap?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> remove the gray base cap. Throw away the Pen and get a new Pen.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if there is a drop of liquid on the tip of the needle when I remove the gray base cap?</content>
                  </paragraph>
                  <paragraph>A drop of liquid on the tip of the needle is normal. <content styleCode="bold">Do not</content> touch the needle.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do I need to hold the injection button down until the injection is complete?</content>
                  </paragraph>
                  <paragraph>This is not necessary, but it may help you keep the Pen steady against your skin.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">I heard more than 2 clicks during my injectionâ2 loud clicks and 1 soft one. Did I get my complete injection?</content>
                  </paragraph>
                  <paragraph>Some people may hear a soft click right before the second loud click. That is the normal operation of the Pen. <content styleCode="bold">Do not</content> remove the Pen from your skin until you hear the second loud click.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">I am not sure if my Pen worked the right way.</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="19.150%" align="left"/>
                     <col width="80.850%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f14" referencedObject="mm14"/>
                           </td>
                           <td align="left" valign="top">Check to see if you have received your dose. Your dose was delivered the right way if the gray plunger is visible. Also, see <content styleCode="bold">
                                 <linkHtml href="#p02">Step 4</linkHtml>
                              </content> of the instructions.<br/>If you do not see the gray plunger, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) for further instructions. Until then, store your Pen safely to avoid an accidental needle stick.<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What if there is a drop of liquid or blood on my skin after my injection?</content>
                  </paragraph>
                  <paragraph>This is normal. Press a cotton ball or gauze over the injection site. <content styleCode="bold">Do not</content> rub the injection site.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Other information</content>
                  </paragraph>
                  <paragraph>â¢ If you have vision problems, <content styleCode="bold">do not</content> use your Pen without help from a person trained to use the MOUNJARO Pen.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Where to learn more</content>
                  </paragraph>
                  <paragraph>â¢ If you have questions or problems with your MOUNJARO Pen, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider.
</paragraph>
                  <paragraph>â¢ For more information about the MOUNJARO Pen, visit our website at www.mounjaro.com.
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="14.167%" align="left"/>
                     <col width="36.667%" align="left"/>
                     <col width="49.167%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f15" referencedObject="mm15"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Scan this code to launch <br/>www.mounjaro.com</content>
                           </td>
                           <td align="left" valign="top"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Marketed by:
</paragraph>
                  <paragraph>Lilly USA, LLC
</paragraph>
                  <paragraph>Indianapolis, IN 46285, USA
</paragraph>
                  <paragraph>MOUNJARO is a registered trademark of Eli Lilly and Company.
</paragraph>
                  <paragraph>Copyright Â© 2022, 2024, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: May 2024
</paragraph>
                  <paragraph>MOU-0003-IFU-20240516
</paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f16" referencedObject="mm16"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm04">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-1-v3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm05">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-2-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm06">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-3-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm07">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-4a-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm08">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-4b-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm09">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-5-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm10">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-6-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm11">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-7-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm12">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-8-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm13">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-9-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm14">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-pen-ifu-10-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm15">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-qr.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm16">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s98">
               <id root="a0c6014e-0009-40ef-9cc5-4679efbeb7e9"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Mounjaro Single-Dose Vial Instructions for Use</title>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="justify" valign="bottom">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              <br/>
                              <content styleCode="bold">MOUNJARO<sup>Â®</sup> [mown-JAHR-OH]</content>
                              <br/>
                              <content styleCode="bold">(tirzepatide)</content>
                              <br/>
                              <content styleCode="bold">injection, for subcutaneous use</content>
                              <br/>
                              <br/>
                              <content styleCode="bold">2.5Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">5Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">7.5Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">10Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">12.5Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">15Â mg/0.5Â mL single-dose vial</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before injecting MOUNJARO</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read this Instructions for Use before you start taking MOUNJARO and each time you get a new vial.</content> There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
						</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not share your needles or syringes with other people. You may give other people a serious infection or get a serious infection from them.</content>
                  </paragraph>
                  <paragraph>Talk to your healthcare provider about how to inject MOUNJARO the right way.</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>MOUNJARO is a single-dose vial.</item>
                     <item>MOUNJARO is used 1 time each week.</item>
                     <item>Inject under the skin (subcutaneously) only.</item>
                     <item>You or another person may inject into your stomach (abdomen) or thigh.</item>
                     <item>Another person can inject into the back of your upper arm.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Gather supplies needed to give your injection</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>1 single-dose MOUNJARO vial
</item>
                     <item>1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)
</item>
                     <item>1 alcohol swab
</item>
                     <item>gauze
</item>
                     <item>1 sharps container for throwing away used needles and syringes. <content styleCode="bold">See</content> âDisposing of used needles and syringesâ at the end of these instructions.
</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="20.000%" align="left"/>
                     <col width="80.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle">
                              <content styleCode="bold">Guide to parts<br/>
                                 <br/>Vial</content>
                           </td>
                           <td align="center" valign="middle">
                              <content styleCode="bold">Needle and Syringe (not included)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <renderMultiMedia ID="f34a" referencedObject="mm34a"/>
                           </td>
                           <td align="center" valign="middle">
                              <renderMultiMedia ID="f34b" referencedObject="mm34b"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Note:</content> The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Preparing to inject MOUNJARO</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Remove the vial</content>  from the refrigerator.
						</paragraph>
                  <paragraph>
                     <content styleCode="bold">Check the vial</content> label to make sure you have the right medicine and dose, and that it has not expired.
						</paragraph>
                  <paragraph>Make sure the medicine:</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50%" align="left"/>
                     <col width="50%" align="left"/>
                     <tbody>
                        <tr>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>is not frozen</item>
                                 <item>is not cloudy</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>is colorless to slightly yellow</item>
                                 <item>does not have particles</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Wash your hands with soap and water.</content>
                  </paragraph>
                  <table width="100%">
                     <col width="53.250%" align="left"/>
                     <col width="46.750%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Step 1:</content>
                              <br/>Pull off the plastic protective cap. <content styleCode="bold">Do not</content> remove the rubber stopper.
</td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <renderMultiMedia ID="f35" referencedObject="mm35"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 2:</content>
                              <br/>Wipe the rubber stopper with an alcohol swab.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f36" referencedObject="mm36"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 3:</content>
                              <br/>Remove the outer wrapping from the syringe.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f37" referencedObject="mm37"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 4:</content>
                              <br/>Remove the outer wrapping from the needle.<br/>The syringe that your healthcare provider recommended may have a pre-attached needle. If the needle is attached, skip to step 6.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f38" referencedObject="mm38"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 5:</content>
                              <br/>Place the needle on top of the syringe and turn until it is tight and firmly attached.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f39" referencedObject="mm39"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 6:</content>
                              <br/>Remove the needle shield by pulling straight off.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f40" referencedObject="mm40"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 7:</content>
                              <br/>Hold the syringe in one hand with the needle pointing up. With the other hand pull down on the plunger until the plunger tip reaches the line on the syringe indicating that 0.5Â mL of air has been drawn into the syringe.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f41" referencedObject="mm41"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 8:</content>
                              <br/>Push the needle through the rubber stopper of the vial.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f42" referencedObject="mm42"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 9:</content>
                              <br/>Push the plunger all the way in. This puts air into the vial and makes it easier to pull the solution from the vial.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f43" referencedObject="mm43"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Step 10: </content>
                              <br/>Turn the vial and syringe upside down. Make sure that the tip of the needle is in the liquid and slowly pull the plunger down until the plunger tip is past the 0.5 mL line.<br/> If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top.
</td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <renderMultiMedia ID="f44" referencedObject="mm44"/>
                              <renderMultiMedia ID="f45" referencedObject="mm45"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 11:</content>
                              <br/>Slowly push the plunger up until the plunger tip reaches the 0.5 mL line.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f46" referencedObject="mm46"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 12:</content>
                              <br/>Pull the syringe out of the rubber stopper of the vial.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f47" referencedObject="mm47"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Injecting MOUNJARO </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.</item>
                     <item>
                        <content styleCode="bold">Change (rotate) your injection site within the area you choose for each dose</content> to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.</item>
                     <item>
                        <content styleCode="bold">Do not</content> inject where the skin has pits, is thickened, or has lumps.</item>
                     <item>
                        <content styleCode="bold">Do not</content> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.</item>
                     <item>
                        <content styleCode="bold">Do not</content> mix MOUNJARO with any other medicine.</item>
                     <item>
                        <content styleCode="bold">Do not</content> inject MOUNJARO in the same injection site used for other medicines.</item>
                  </list>
                  <table width="100%">
                     <col width="53.250%" align="left"/>
                     <col width="46.750%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Step 13: </content>
                              <br/>Choose your injection site.
	<br/> You can inject MOUNJARO under the skin (subcutaneously) of your stomach area (abdomen) or thighs.
	<br/> Someone else can inject in your stomach area, thighs, or the back of the upper arms.

</td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <renderMultiMedia ID="f48" referencedObject="mm48"/>
                              <renderMultiMedia ID="f49" referencedObject="mm49"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 14:</content>
                              <br/>Insert the needle into your skin.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f50" referencedObject="mm50"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 15:</content>
                              <br/>Push down on the plunger to inject your dose.
										<br/>The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your dose.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f51" referencedObject="mm51"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 16:</content>
                              <br/>Pull the needle out of your skin.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. <content styleCode="bold">Do not</content> rub the area.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> recap the needle. Recapping the needle can lead to a needle stick injury.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f52" referencedObject="mm52"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Disposing of used needles and syringes</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) loose needles and syringes in your household trash.</item>
                     <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
							<list listType="unordered">
                           <item>
                              <caption>-
</caption> made of a heavy-duty plastic,</item>
                           <item>
                              <caption>-
</caption> can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                           <item>
                              <caption>-
</caption> upright and stable during use,</item>
                           <item>
                              <caption>-
</caption> leak-resistant, and</item>
                           <item>
                              <caption>-
</caption> properly labeled to warn of hazardous waste inside the container.</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDAâs website at: <br/>
	http://www.fda.gov/safesharpsdisposal.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storing MOUNJARO</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store all unopened vials in the refrigerator at 36Â°F to 46Â°F (2Â°C to 8Â°C).
</item>
                     <item>You may store the unopened vial at room temperature up to 86Â°F (30Â°C) for up to 21 days.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> freeze. <content styleCode="bold">Do not</content> use if MOUNJARO has been frozen.</item>
                     <item>Store the vial in the original carton to protect from light.
</item>
                     <item>Throw away all opened vials after use, even if there is medicine left in the vial.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep MOUNJARO vials, syringes, needles, and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>If you have any questions or problems with your MOUNJARO, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Marketed by:<br/> Lilly USA, LLC  <br/> Indianapolis, IN 46285, USA</content>
                  </paragraph>
                  <paragraph>MOUNJARO is a registered trademark of Eli Lilly and Company.
</paragraph>
                  <paragraph>Copyright Â© 2023, 2024, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>MON-VL-0002-IFU-20240229
</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: February 2024
</paragraph>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm34a">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-1-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm34b">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-2-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm35">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-3-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm36">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-4-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm37">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-5-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm38">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-6-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm39">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-7-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm40">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-8-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm41">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-9-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm42">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-10-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm43">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-11-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm44">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-12-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm45">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-13-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm46">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-14-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm47">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-15-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm48">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-16-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm49">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-17-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm50">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-18-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm51">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-19-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm52">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-ifu-20-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s99">
               <id root="d1a3114f-0591-498b-ac74-596787fa4b36"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 2.5 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-1506-80
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>2.5 mg/0.5 mL
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>4 x 2.5 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f22" referencedObject="mm22"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm22">
                     <text>PACKAGE LABEL - Mounjaro  2.5 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-cart-2point5mg-066-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s100">
               <id root="a345692d-04c8-4c5e-8526-5d4fcb6b1d1c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 5 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-1495-80
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>5 mg/0.5 mL
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>4 x 5 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f23" referencedObject="mm23"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm23">
                     <text>PACKAGE LABEL - Mounjaro 5 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-cart-5mg-067-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s101">
               <id root="13a3eef5-6da1-4607-91f9-4e185e1722ff"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 7.5 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-1484-80
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>7.5 mg/0.5 mL
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>4 x 7.5 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f24" referencedObject="mm24"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm24">
                     <text>PACKAGE LABEL - Mounjaro 7.5 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-cart-7point5mg-068-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s102">
               <id root="04df5c1b-6a71-4149-8158-5b8aed116e98"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 10 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-1471-80
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>10 mg/0.5 mL
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>4 x 10 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f25" referencedObject="mm25"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm25">
                     <text>PACKAGE LABEL - Mounjaro 10 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-cart-10mg-069-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s103">
               <id root="c6df04c1-fdb0-4b4e-8087-bc6ef49a6a43"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 12.5 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-1460-80
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>12.5 mg/0.5 mL
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>4 x 12.5 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f26" referencedObject="mm26"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm26">
                     <text>PACKAGE LABEL - Mounjaro 12.5 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-cart-12point5mg-070-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s104">
               <id root="b2e126da-19f9-4756-b508-cfb2e1b34cdc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 15 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-1457-80
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>15 mg/0.5 mL
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>4 x 15 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f27" referencedObject="mm27"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm27">
                     <text>PACKAGE LABEL - Mounjaro 15 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-cart-15mg-071-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s105">
               <id root="c1b46ffc-6523-44b1-b2df-6894b0fc20c6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>,  2.5 mg/0.5 mL, Carton, Single-dose Vial</content>
                  </paragraph>
                  <paragraph>NDC 0002-1152-01
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>2.5 mg/0.5 mL
</paragraph>
                  <paragraph>Single-dose Vial - discard unused portion
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f28" referencedObject="mm28"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm28">
                     <text>PACKAGE LABEL - Mounjaro 2.5 mg/0.5 mL, Single-dose Vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-2point5mg-nl037.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s106">
               <id root="8d6e0478-ec04-4ab3-94a4-bba367aae330"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 5 mg/0.5 mL, Single-dose Vial</content>
                  </paragraph>
                  <paragraph>NDC 0002-1243-01
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>5 mg/0.5 mL
</paragraph>
                  <paragraph>Single-dose Vial - discard unused portion
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f29" referencedObject="mm29"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm29">
                     <text>PACKAGE LABEL - Mounjaro 5 mg/0.5 mL, Single-dose Vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-5mg-nl038.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s107">
               <id root="7dc69292-a545-4523-a7da-eca57107f63e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 7.5 mg/0.5 mL, Single-dose Vial</content>
                  </paragraph>
                  <paragraph>NDC 0002-2214-01
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>7.5 mg/0.5 mL
</paragraph>
                  <paragraph>Single-dose Vial - discard unused portion
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f30" referencedObject="mm30"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm30">
                     <text>PACKAGE LABEL - Mounjaro 7.5 mg/0.5 mL, Single-dose Vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-7point5mg-nl039.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s108">
               <id root="e36a81b6-9c45-4787-b26e-480041f5b15a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 10 mg/0.5 mL, Carton, Single-dose Vial</content>
                  </paragraph>
                  <paragraph>NDC 0002-2340-01
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>10 mg/0.5 mL
</paragraph>
                  <paragraph>Single-dose Vial - discard unused portion
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f31" referencedObject="mm31"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm31">
                     <text>PACKAGE LABEL - Mounjaro 10 mg/0.5 mL, Single-dose Vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-10mg-nl040.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s109">
               <id root="6dd2879a-d7c9-4fa4-8a88-84180d4064df"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 12.5 mg/0.5 mL, Single-dose Vial</content>
                  </paragraph>
                  <paragraph>NDC 0002-2423-01
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>12.5 mg/0.5 mL
</paragraph>
                  <paragraph>Single-dose Vial - discard unused portion
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f32" referencedObject="mm32"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm32">
                     <text>PACKAGE LABEL - Mounjaro 12.5 mg/0.5 mL, Single-dose Vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-12point5mg-nl041.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s110">
               <id root="aff46971-b6c3-44f5-8bb1-f70839e9bba6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Mounjaro<sup>Â®</sup>, 15 mg/0.5 mL, Single-dose Vial</content>
                  </paragraph>
                  <paragraph>NDC 0002-3002-01
</paragraph>
                  <paragraph>Mounjaro<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>15 mg/0.5 mL
</paragraph>
                  <paragraph>Single-dose Vial - discard unused portion
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f33" referencedObject="mm33"/>
               </text>
               <effectiveTime value="20240516"/>
               <component>
                  <observationMedia ID="mm33">
                     <text>PACKAGE LABEL - Mounjaro 15 mg/0.5 mL, Single-dose Vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="moun-vial-15mg-nl042.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>